Search Results for: CTNNB1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
MITF melanocyte inducing transcription factor
  • SUMOylation of transcription factors
  • Ocular albinism; Ocular albinism, type I (OA1); Waardenburg syndrome, type II (WS2-OA)
  • Waardenburg syndrome (WS)
  • Malignant melanoma
PSEN1 presenilin 1
  • Nuclear signaling by ERBB4
  • Degradation of the extracellular matrix
  • Regulated proteolysis of p75NTR
  • NRIF signals cell death from the nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • EPH-ephrin mediated repulsion of cells
  • Neutrophil degranulation
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Noncanonical activation of NOTCH3
  • Acne inversa; Hidradenitis supprativa
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Alzheimer's disease (AD)
PTGS2 prostaglandin-endoperoxide synthase 2
  • Nicotinamide salvaging
  • Synthesis of 15-eicosatetraenoic acid derivatives
  • Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • Biosynthesis of DHA-derived SPMs
  • Biosynthesis of EPA-derived SPMs
  • Biosynthesis of DPAn-3 SPMs
  • Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives
  • Dihomo-gamma-linolenic acid
  • Icosapent
  • Aminosalicylic acid
  • Mesalazine
  • Acetaminophen
  • Indomethacin
  • Nabumetone
  • Ketorolac
  • Tenoxicam
  • Lenalidomide
  • Celecoxib
  • Tolmetin
  • Rofecoxib
  • Piroxicam
  • Fenoprofen
  • Valdecoxib
  • Diclofenac
  • Sulindac
  • Flurbiprofen
  • Etodolac
  • Mefenamic acid
  • Naproxen
  • Sulfasalazine
  • Phenylbutazone
  • Meloxicam
  • Carprofen
  • Diflunisal
  • Suprofen
  • Salicylic acid
  • Meclofenamic acid
  • Acetylsalicylic acid
  • Bromfenac
  • Oxaprozin
  • Ketoprofen
  • Balsalazide
  • Thalidomide
  • Ibuprofen
  • Lumiracoxib
  • Magnesium salicylate
  • Salsalate
  • Choline magnesium trisalicylate
  • Ginseng
  • Antrafenine
  • Antipyrine
  • Tiaprofenic acid
  • Etoricoxib
  • Flufenamic acid
  • Resveratrol
  • 1-Phenylsulfonamide-3-Trifluoromethyl-5-Parabromophenylpyrazole
  • Prostaglandin G2
  • Niflumic acid
  • Licofelone
  • Nimesulide
  • Cimicoxib
  • Lornoxicam
  • Aceclofenac
  • Nepafenac
  • Parecoxib
  • Pomalidomide
  • Cannabidiol
  • Loxoprofen
  • Dexibuprofen
  • Dexketoprofen
  • Droxicam
  • Tolfenamic acid
  • Firocoxib
  • Morniflumate
  • Propacetamol
  • Talniflumate
  • Phenyl salicylate
  • Trolamine salicylate
  • Menthyl salicylate
  • Glycol salicylate
  • Dipyrithione
  • Bryostatin 1
  • Alclofenac
  • Bufexamac
  • Bendazac
  • Acemetacin
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Esophageal cancer
  • Cholangiocarcinoma
  • Penile cancer
TGFBR2 transforming growth factor beta receptor 2
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Foreskin fibroblast (neonatal)
  • Foreskin keratinocyte (neonatal)
  • Fostamatinib
  • Colorectal cancer
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
AXIN1 axin 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Degradation of AXIN
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Ub-specific processing proteases
  • RUNX1 regulates estrogen receptor mediated transcription
  • RUNX1 regulates transcription of genes involved in WNT signaling
  • Estrogen-dependent gene expression
  • 1,4-Dithiothreitol
  • Hepatocellular carcinoma
  • Caudal duplication anomaly
AXIN2 axin 2
  • TCF dependent signaling in response to WNT
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Degradation of AXIN
  • Ub-specific processing proteases
  • Tooth agenesis; Hypodontia
  • Oligodontia-colorectal cancer syndrome
BRCA1 BRCA1 DNA repair associated
  • Meiotic synapsis
  • SUMOylation of DNA damage response and repair proteins
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Transcriptional Regulation by E2F6
  • Meiotic recombination
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
  • Breast cancer
  • Ovarian cancer
CDH3 cadherin 3
  • Adherens junctions interactions
  • Hypotrichosis, congenital, with juvenile macular dystrophy
  • Ectodermal dysplasia, ectrodactyly, and macular dystrophy (EEM syndrome)
FHIT fragile histidine triad diadenosine triphosphatase
  • Adenosine monotungstate
  • Ado-P-Ch2-P-Ps-Ado
  • Non-small cell lung cancer
  • Small cell lung cancer
FUS FUS RNA binding protein
  • mRNA Splicing - Major Pathway
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Myxoid liposarcoma
KMT2A lysine methyltransferase 2A
  • PKMTs methylate histone lysines
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Transcriptional regulation of granulopoiesis
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
NF2 neurofibromin 2
  • Regulation of actin dynamics for phagocytic cup formation
  • RHO GTPases activate PAKs
  • Malignant pleural mesothelioma
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
NOTCH1 notch receptor 1
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
  • Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Bicuspid aortic valve
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
NR5A1 nuclear receptor subfamily 5 group A member 1
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Transcriptional regulation of pluripotent stem cells
  • Transcriptional regulation of testis differentiation
  • (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE
  • Phosphatidyl ethanol
  • Premature ovarian failure
  • 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
TGFBR1 transforming growth factor beta receptor 1
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGFBR1 LBD Mutants in Cancer
  • UCH proteinases
  • Ub-specific processing proteases
  • 4-(3-Pyridin-2-Yl-1h-Pyrazol-4-Yl)Quinoline
  • Naphthyridine Inhibitor
  • 3-(4-Fluorophenyl)-2-(6-Methylpyridin-2-Yl)-5,6-Dihydro-4h-Pyrrolo[1,2-B]Pyrazole
  • N-[4-(5-fluoro-6-methylpyridin-2-yl)-5-quinoxalin-6-yl-1H-imidazol-2-yl]acetamide
  • 2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
  • N-1H-indazol-5-yl-2-(6-methylpyridin-2-yl)quinazolin-4-amine
  • Fostamatinib
  • Loeys-Dietz syndrome (LDS)
  • Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
AKT1 AKT serine/threonine kinase 1
  • Activation of BAD and translocation to mitochondria
  • PIP3 activates AKT signaling
  • PIP3 activates AKT signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • MTOR signalling
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the cytosol
  • AKT phosphorylates targets in the nucleus
  • Negative regulation of the PI3K/AKT network
  • eNOS activation
  • AKT-mediated inactivation of FOXO1A
  • Integrin signaling
  • Deactivation of the beta-catenin transactivating complex
  • CD28 dependent PI3K/Akt signaling
  • CTLA4 inhibitory signaling
  • G beta:gamma signalling through PI3Kgamma
  • Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
  • KSRP (KHSRP) binds and destabilizes mRNA
  • VEGFR2 mediated vascular permeability
  • TP53 Regulates Metabolic Genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Interleukin-4 and Interleukin-13 signaling
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Association with Co-factors
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • RAB GEFs exchange GTP for GDP on RABs
  • RUNX2 regulates genes involved in cell migration
  • Regulation of PTEN stability and activity
  • Extra-nuclear estrogen signaling
  • Negative regulation of NOTCH4 signaling
  • FLT3 Signaling
  • Regulation of localization of FOXO transcription factors
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • ATP
  • Arsenic trioxide
  • Genistein
  • Inositol 1,3,4,5-Tetrakisphosphate
  • Resveratrol
  • Archexin
  • Enzastaurin
  • Perifosine
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
AMER1 APC membrane recruitment protein 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Osteopathia striata with cranial sclerosis
APC2 APC regulator of WNT signaling pathway 2
  • Colorectal cancer
APP amyloid beta precursor protein
  • Platelet degranulation
  • ECM proteoglycans
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • G alpha (i) signalling events
  • Lysosome Vesicle Biogenesis
  • Formyl peptide receptors bind formyl peptides and many other ligands
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • The NLRP3 inflammasome
  • Advanced glycosylation endproduct receptor signaling
  • Advanced glycosylation endproduct receptor signaling
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Post-translational protein phosphorylation
  • TRAF6 mediated NF-kB activation
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
  • Purinergic signaling in leishmaniasis infection
  • Amyloid fiber formation
  • Deferoxamine
  • Aluminium
  • Zinc
  • L-methionine (R)-S-oxide
  • Resveratrol
  • Tromethamine
  • Phenserine
  • Tetrathiomolybdate
  • CAD106
  • Mito-4509
  • Edonerpic
  • Dimercaprol
  • Copper
  • Florbetaben (18F)
  • Florbetapir (18F)
  • Flutemetamol (18F)
  • Zinc acetate
  • Aluminium phosphate
  • Aluminum acetate
  • Zinc chloride
  • Zinc sulfate, unspecified form
  • Alzheimer's disease (AD)
BCL6 BCL6 transcription repressor
  • Interleukin-4 and Interleukin-13 signaling
  • TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
  • FOXO-mediated transcription of cell death genes
  • Hairy-cell leukemia

Page 2 out of 10 pages